Clinical Trials Arena on MSN
Roche’s KRAS blocker touts best-in-class NSCLC potential in Phase III trial
Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).
Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the ...
Roche RHHBY reported positive results from the late-stage Krascendo 1 study evaluating experimental candidate, divarasib, in patients with previously treated KRAS G12C non-small cell lung cancer ...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer ; Divarasib showed clinically meani ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for the ...
SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug ...
SAN FRANCISCO and SUZHOU, China, Aug. 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
KRAS G12C occurs in ~3%–4% of CRC, translating to a sizable metastatic population with limited options and strong rationale for KRAS G12C inhibition strategies. Dual KRAS–EGFR blockade leverages ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...
--Amgen today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib in 126 patients with KRAS G12C- mutated advanced non-small cell lung ...
JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results